Pharmather Holdings Ltd
CNSX:PHRM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Lipella Pharmaceuticals Inc
OTC:LIPO
|
US |
|
Tali Digital Ltd
ASX:TD1
|
AU |
|
L
|
Live Energy Minerals Corp
CNSX:LIVE
|
CA |
|
I
|
IC Capitalight Corp
CNSX:IC
|
CA |
|
B
|
BrainAurora Medical Technology Ltd
HKEX:6681
|
CN |
|
G
|
Guangzhou Rural Commercial Bank Co Ltd
HKEX:1551
|
CN |
|
BAE Systems PLC
LSE:BA
|
UK |
Pharmather Holdings Ltd
Research & Development
Pharmather Holdings Ltd
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
P
|
Pharmather Holdings Ltd
CNSX:PHRM
|
Research & Development
-CA$581.6k
|
CAGR 3-Years
39%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bausch Health Companies Inc
TSX:BHC
|
Research & Development
-$629m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-7%
|
|
|
X
|
Xenon Pharmaceuticals Inc
NASDAQ:XENE
|
Research & Development
-$300.9m
|
CAGR 3-Years
-42%
|
CAGR 5-Years
-43%
|
CAGR 10-Years
-35%
|
|
|
K
|
Knight Therapeutics Inc
TSX:GUD
|
Research & Development
-CA$29m
|
CAGR 3-Years
-25%
|
CAGR 5-Years
-20%
|
CAGR 10-Years
-27%
|
|
|
Spectral Medical Inc
TSX:EDT
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Cipher Pharmaceuticals Inc
TSX:CPH
|
Research & Development
-$21k
|
CAGR 3-Years
33%
|
CAGR 5-Years
31%
|
CAGR 10-Years
35%
|
|
Pharmather Holdings Ltd
Glance View
PharmaTher Holdings Ltd. is a specialty psychedelic pharmaceutical company, which engages in the research, development and commercialization of ketamine and novel microneedle patches for delivering psychedelics to treat neuropsychiatric, neurodegenerative, and pain disorders. The company is headquartered in Toronto, British Columbia. The company went IPO on 2020-10-09. The firm is focused on the research, development and commercialization uses, formulations and delivery methods of psychedelics to treat mental illness, neurological and pain disorders. The firm's product pipeline targets the use of ketamine to treat Parkinson’s disease, depression, amyotrophic lateral sclerosis (Lou Gehrig’s disease) and pain. The firm is also focused on developing a microneedle patch to deliver ketamine and other psychedelics, such as psilocybin, N, N-Dimethyltryptamine (DMT), Lysergic acid diethylamide (LSD) and 3,4-Methylenedioxymethamphetamine (MDMA).
See Also
What is Pharmather Holdings Ltd's Research & Development?
Research & Development
-581.6k
CAD
Based on the financial report for May 31, 2025, Pharmather Holdings Ltd's Research & Development amounts to -581.6k CAD.
What is Pharmather Holdings Ltd's Research & Development growth rate?
Research & Development CAGR 3Y
39%
Over the last year, the Research & Development growth was 73%. The average annual Research & Development growth rates for Pharmather Holdings Ltd have been 39% over the past three years .
